Apelin in Willis Ekbom Disease

Acibadem University30 enrolled

Overview

The purpose of this study is to assess apelin level in patients with Willis-Ekbom Disease (WED) as known Restless Legs Syndrome (RLS). Cardiovascular complications of WED have been reported in recent studies. Increased oxidative stress is thought to play an important role in cardiovascular complications of WED patients. Apelin is a novel described antioxidant bioactive peptide. The investigators hypothesize that patients with WED have lower plasma apelin level than healthy subjects based on presence of oxidative stress of WED.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Restless Legs Syndrome

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed as RLS/WED according to International Classification of Sleep Disorders (ICSD-3) criteria * Patients with idiopathic RLS/WED * Moderate and severe RLS/WED according to International Restless Legs Syndrome Rating Scale * Periodic Leg Movements Index above 5 in polysomnography record * BMI below 25 Exclusion Criteria: * Disorders which cause symptomatic RLS(Iron deficiency anemia, kidney failure, diabetes mellitus, pregnancy, Parkinson's disease, multiple sclerosis, neuropathy) * Systemic diseases which cause possible oxidative stress status (cardiovascular diseases, obesity, diabetes mellitus, use of any medical drugs especially ACE inhibitors e.g.) * Another sleep disorder

Outcomes

Primary Outcomes

Serum apelin level in WED patients and healthy controls

Time frame: Two months

Central Contacts

Selda Korkmaz, Assist. Prof. Dr.

CONTACT

00905325807889 korkmazs78@gmail.com

Tugce Bilecenoglu, M.D.

CONTACT

00905386275515 nedimetugche@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.